Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Common Equity (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Common Equity for 3 consecutive years, with $305.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 34.08% to $305.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $305.7 million, a 34.08% decrease, with the full-year FY2025 number at $305.7 million, down 34.08% from a year prior.
  • Common Equity was $305.7 million for Q4 2025 at Nuvation Bio, down from $325.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $641.1 million in Q1 2023 to a low of $257.2 million in Q2 2024.
  • A 3-year average of $477.0 million and a median of $483.3 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: tumbled 58.82% in 2024, then surged 44.99% in 2025.
  • Nuvation Bio's Common Equity stood at $605.1 million in 2023, then dropped by 23.36% to $463.8 million in 2024, then crashed by 34.08% to $305.7 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Common Equity are $305.7 million (Q4 2025), $325.9 million (Q3 2025), and $372.9 million (Q2 2025).